| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| S Frangou, M Lewi. Atypical antipsychotics in ordinary clinical practice: a pharmaco-epidemiologic survey in a south London service. European psychiatry : the journal of the Association of European Psychiatrists. vol 15. issue 3. 2000-08-24. PMID:10881220. |
the aim of this paper was to examine the use of atypical antipsychotics in clinical care, by means of a survey of prescribing practices for clozapine, risperidone, olanzapine, sertindole and quetiapine for all patients treated for dsm-iv schizophrenia within a psychiatric service. |
2000-08-24 |
2023-08-12 |
Not clear |
| S Frangou, M Lewi. Atypical antipsychotics in ordinary clinical practice: a pharmaco-epidemiologic survey in a south London service. European psychiatry : the journal of the Association of European Psychiatrists. vol 15. issue 3. 2000-08-24. PMID:10881220. |
the new atypical antipsychotics appear to be replacing older neuroleptics as the first-line treatment of schizophrenia while clozapine is mostly reserved for poor responders. |
2000-08-24 |
2023-08-12 |
Not clear |
| P Falkai, K Vogele. [The chances of new atypical substances]. Fortschritte der Neurologie-Psychiatrie. vol 68 Suppl 1. 2000-08-24. PMID:10907611. |
all of these newly developed, atypical antipsychotics show a high degree of efficacy in the treatment of positive symptoms of schizophrenia in combination with a lack of or a reduced degree of extrapyramidal side effects (eps). |
2000-08-24 |
2023-08-12 |
Not clear |
| P J Harriso. Neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. Focus on dopamine (D1, D3, D4) and 5-HT2a receptors. The British journal of psychiatry. Supplement. issue 38. 2000-07-31. PMID:10884896. |
neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. |
2000-07-31 |
2023-08-12 |
Not clear |
| T Sharm. Cognitive effects of conventional and atypical antipsychotics in schizophrenia. The British journal of psychiatry. Supplement. issue 38. 2000-07-31. PMID:10884899. |
cognitive effects of conventional and atypical antipsychotics in schizophrenia. |
2000-07-31 |
2023-08-12 |
Not clear |
| C Doubremelle, B Millet, J P Oli. [Schizophrenic with obsessive-compulsive disorder or symptoms]. L'Encephale. vol 26. issue 2. 2000-07-24. PMID:10858921. |
finally, schizophrenia treated by atypical antipsychotics can be complicated by obsessive compulsive symptoms following the onset of the drug. |
2000-07-24 |
2023-08-12 |
Not clear |
| H E Shannon, K Rasmussen, F P Bymaster, J C Hart, S C Peters, M D Swedberg, L Jeppesen, M J Sheardown, P Sauerberg, A Fink-Jense. Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophrenia research. vol 42. issue 3. 2000-07-11. PMID:10785583. |
the present results thus demonstrate that xanomeline has a pharmacologic profile which is similar to that of the atypical antipsychotics clozapine and olanzapine, thus indicating that xanomeline has the potential to be a novel approach in the treatment of psychotic symptoms in patients with schizophrenia. |
2000-07-11 |
2023-08-12 |
mouse |
| V Kumari, W Soni, V M Mathew, T Sharm. Prepulse inhibition of the startle response in men with schizophrenia: effects of age of onset of illness, symptoms, and medication. Archives of general psychiatry. vol 57. issue 6. 2000-06-07. PMID:10839340. |
prepulse inhibition deficits in schizophrenia seem to be partially normalized by typical antipsychotics and more fully by some atypical antipsychotics. |
2000-06-07 |
2023-08-12 |
Not clear |
| R R Conley, H Y Meltze. Adverse events related to olanzapine. The Journal of clinical psychiatry. vol 61 Suppl 8. 2000-05-18. PMID:10811240. |
olanzapine, a serotonin-dopamine receptor antagonist, is one of the novel atypical antipsychotics that is effective against the positive and negative symptoms of schizophrenia with significantly fewer treatment-emergent extrapyramidal symptoms and less akathisia associated with traditional antipsychotics. |
2000-05-18 |
2023-08-12 |
Not clear |
| R R Conley, H Y Meltze. Adverse events related to olanzapine. The Journal of clinical psychiatry. vol 61 Suppl 8. 2000-05-18. PMID:10811240. |
because of the comparative efficacy and improved side effect profiles of the atypical antipsychotics, consideration should be given to using the newer agents as preferred treatment for schizophrenia and related psychoses. |
2000-05-18 |
2023-08-12 |
Not clear |
| T H Svensso. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Brain research. Brain research reviews. vol 31. issue 2-3. 2000-05-17. PMID:10719159. |
the present paper describes experimental work aimed at elucidating this critical question, utilizing the phencyclidine (pcp) model of schizophrenia in combination with studies of typical and atypical antipsychotics as well as various specific receptor blocking agents. |
2000-05-17 |
2023-08-12 |
rat |
| M Maes, L Bocchio Chiavetto, S Bignotti, G Battisa Tura, R Pioli, F Boin, G Kenis, E Bosmans, R de Jongh, A Lin, G Racagni, C A Altamur. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 10. issue 2. 2000-05-08. PMID:10706993. |
it is concluded that (i) schizophrenia and, in particular, trs is characterized by an activation of the monocytic arm of cell-mediated immunity and (ii) atypical antipsychotics may decrease the anti-inflammatory capacity of the serum in trs patients. |
2000-05-08 |
2023-08-12 |
human |
| P E Keck, S M Strakowski, S L McElro. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. The Journal of clinical psychiatry. vol 61 Suppl 3. 2000-03-22. PMID:10724127. |
the efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. |
2000-03-22 |
2023-08-12 |
Not clear |
| P E Keck, S M Strakowski, S L McElro. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. The Journal of clinical psychiatry. vol 61 Suppl 3. 2000-03-22. PMID:10724127. |
these studies suggest that atypical antipsychotics may exert therapeutic effects on depression and hostility as well as psychosis and that clozapine and olanzapine may reduce suicidality in patients with schizophrenia. |
2000-03-22 |
2023-08-12 |
Not clear |
| M Masellis, V S Basile, V Ozdemir, H Y Meltzer, F M Macciardi, J L Kenned. Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine. Biological psychiatry. vol 47. issue 3. 2000-03-17. PMID:10682223. |
the reintroduction of clozapine, the prototype of atypical antipsychotics, in the late 1980s has led to significant advances in the pharmacological management of schizophrenia. |
2000-03-17 |
2023-08-12 |
Not clear |
| J A Worrel, P A Marken, S E Beckman, V L Ruehte. Atypical antipsychotic agents: a critical review. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. vol 57. issue 3. 2000-03-09. PMID:10674777. |
head-to-head comparisons of atypical antipsychotics in non-treatment-resistant schizophrenia have been inconclusive. |
2000-03-09 |
2023-08-12 |
Not clear |
| J A Worrel, P A Marken, S E Beckman, V L Ruehte. Atypical antipsychotic agents: a critical review. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. vol 57. issue 3. 2000-03-09. PMID:10674777. |
atypical antipsychotics are often considered first-line agents for treating schizophrenia and are promising treatment alternatives for other psychiatric and neurologic conditions. |
2000-03-09 |
2023-08-12 |
Not clear |
| D I Velligan, A L Mille. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. The Journal of clinical psychiatry. vol 60 Suppl 23. 2000-01-07. PMID:10625197. |
cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. |
2000-01-07 |
2023-08-12 |
Not clear |
| A Breier, P H Ber. The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome. Biological psychiatry. vol 46. issue 3. 1999-12-29. PMID:10435201. |
the psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome. |
1999-12-29 |
2023-08-12 |
Not clear |
| W Zhang, B Pouzet, A L Jongen-Rêlo, I Weiner, J Feldo. Disruption of prepulse inhibition following N-methyl-D-aspartate infusion into the ventral hippocampus is antagonized by clozapine but not by haloperidol: a possible model for the screening of atypical antipsychotics. Neuroreport. vol 10. issue 12. 1999-12-21. PMID:10574365. |
since disruption of ppi is considered to constitute an animal model of schizophrenia that is related to the deficit of sensorimotor gating observed in schizophrenic patients, these results suggest that ppi disruption induced by intra-ventral hippocampal infusions of nmda may serve as an animal model for the selective detection of atypical antipsychotics. |
1999-12-21 |
2023-08-12 |
Not clear |